First in Human, Dose Escalation, Dose Expansion Study of AUR105
This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies.

The study will have two parts: a Dose Escalation Part and Dose Expansion Part.
Solid Tumor, Adult|Non-hodgkin Lymphoma|Hodgkin Lymphoma
DRUG: AUR105
Primary Endpoints, First cycle DLT, 28 Days|Primary Endpoints, PK parameters - Cmax, Day 16|Primary Endpoints, PK parameters- AUC, Day 16|Primary Endpoints, PK parameters- Tmax, Day 16|Primary Endpoints, Recommended Phase 2 Dose determination, Through study completion, an average of 1 year
Exploratory Endpoints:, PD biomarkers (SDMA), Day 15|Exploratory Endpoints:, Efficacy assessments overall response rate, Through study completion, an average of 1 year|Exploratory Endpoints:, Efficacy assessments- duration of response, Through study completion, an average of 1 year|Exploratory Endpoints:, Efficacy assessments- PFS, Through study completion, an average of 1 year|Exploratory Endpoints:, Change in Tumor Specific Markers - CA-125 in ovarian cancer, Through study completion, an average of 1 year|Exploratory Endpoints:, Change in Tumor Specific Markers - PSA in Castrate Resistant Prostate Cancer, Through study completion, an average of 1 year|Exploratory Endpoints:, Change in Tumor Specific Markers - CEA in colorectal cancer, Through study completion, an average of 1 year
This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies.

The study will have two parts. Dose escalation part and Dose expansion part